Ipilimumab was also able to trigger ADCC via the engagement of FcyRIIIA receptors present on primary NK cells as well as NK cells and γδT cells activated by IL-2 by reacting with CTLA-4 present on melanoma cell lines and tissues. Here, CTLA4 is linked to melanoma.